Nebivolol

What it is

Nebivolol is a synthetic beta-blocker sold mainly as Bystolic. It is a mixture of two mirror-image forms: the d-isomer does almost all the beta-blocking, with more than a thousand-fold higher beta-receptor affinity than the l-isomer. It is broken down partly by the liver enzyme CYP2D6, so blood levels differ widely between people depending on which CYP2D6 variants they carry. In the United States it is approved only for high blood pressure.

What the research says

It lowers blood pressure about as well as other common classes, and that is the extent of what has been shown for it. A systematic review of 34 randomised trials in 12,465 people found nebivolol at least as good as other classes at controlling blood pressure, and better than older beta-blockers for diastolic pressure - but the same review states there is a lack of studies showing it reduces death, heart attack or stroke. The Cochrane review of beta-blockers for hypertension found no outcome trials of the newer vasodilating beta-blockers at all, and the US label says there are no controlled trials demonstrating risk reduction with Bystolic. The one outcome trial that exists, SENIORS, was in elderly heart failure, which is not a US-approved use.

Evidence grade: Limited evidence.

How it works

Drug class: Beta-adrenergic blocking agent; a third-generation, highly beta-1-selective beta-blocker with vasodilating properties

It blocks beta-1 adrenergic receptors, which slows the heart and reduces the force of each beat, and it also relaxes blood vessels. The label is candid that how it lowers blood pressure has not been definitively established, listing slower heart rate, weaker contraction, reduced sympathetic outflow from the brain, suppression of renin, and vasodilation as possible contributors. A systematic review attributes the vasodilation partly to nitric oxide released from the vessel lining. (Source 1)

What it is used for

• Nebivolol lowers blood pressure as well as or better than comparator classes across 34 randomised trials, but no trial has shown that nebivolol itself reduces heart attacks, strokes or death, and the label says so explicitly. Benefit is inferred from the class of blood-pressure drugs in general. Evidence: limited. (Source 2)
• SENIORS randomised 2,128 patients aged 70 or over and met its primary composite endpoint (31.1% vs 35.3% on placebo, hazard ratio 0.86, 95% CI 0.74-0.99, P=0.039), but all-cause death alone was not significantly reduced (15.8% vs 18.1%, P=0.21). It is one trial. Evidence: limited. (Source 3)
• SENIORS enrolled patients regardless of ejection fraction and 35% had an ejection fraction above 35%, with no significant influence of ejection fraction on the treatment effect; but no completed trial has tested nebivolol specifically in preserved ejection fraction. We found no outcome data for this use. Evidence: unknown. (Source 4)
• A 2023 pharmacokinetic systematic review states in passing that nebivolol is used for erectile dysfunction, vascular disease and diabetes mellitus, and a narrative review reports no negative effect on erectile function. Neither provides outcome trial evidence that nebivolol treats these conditions, and we found none. Evidence: unknown. (Source 5)

Interactions

• CYP2D6 inhibitors including the antidepressants fluoxetine and paroxetine, plus quinidine and propafenone (pharmacokinetic study): These block the enzyme that clears nebivolol, so blood levels rise and beta-blocking effects - slow heart rate, low blood pressure, fatigue - can become excessive. A pharmacokinetic review documents higher peak levels, exposure and half-life with bupropion, duloxetine, fluvoxamine, paroxetine, lansoprazole and fluoxetine. (Source 5)
• CYP2D6 inhibitors (label position) (label): The label's own instruction is to use caution and that the nebivolol dose may need reducing when a CYP2D6 inhibitor is co-prescribed. (Source 6)
• Verapamil- and diltiazem-type calcium channel blockers, and digoxin and other digitalis glycosides (label): Both slow electrical conduction through the heart and reduce heart rate, so combining them can drop the heart rate, blood pressure and pumping force too far. (Source 6)
• Clonidine, reserpine and guanethidine (label): Sympathetic activity can be reduced excessively. The label specifically says to stop nebivolol several days before clonidine is gradually tapered, because stopping clonidine while a beta-blocker is on board can cause a rebound rise in blood pressure. (Source 6)
• Food (label): No clinically meaningful food interaction is described: the label states it can be taken with or without food. We found no documented grapefruit interaction for nebivolol. (Source 7)
• Dietary supplements, including St John's wort, calcium, iron, magnesium, potassium, fish oil, turmeric and red yeast rice (label): No supplement-specific interaction with nebivolol is documented in the US label or in the systematic reviews we read. The label's drug-interaction section names only CYP2D6 inhibitors, reserpine or clonidine, digitalis glycosides and verapamil- or diltiazem-type calcium channel blockers. Because nebivolol depends on CYP2D6, a supplement that inhibited or induced that enzyme would be expected to change its levels, but we found no study testing one. Absence of a documented interaction is not evidence of safety. (Source 6)
• Insulin and oral diabetes medicines (label): Beta-blockers can hide the warning signs of low blood sugar, such as a racing heart, and can alter glucose levels. The label directs monitoring in people with diabetes. (Source 8)

Stopping it

• Nebivolol should not be stopped abruptly in anyone with coronary artery disease: severe worsening of angina, heart attack and ventricular arrhythmias have been reported after abrupt withdrawal of beta-blockers, sometimes without any warning increase in angina. The label also tells prescribers to caution patients without known coronary disease against interrupting or abruptly stopping it. (Source 9)
• The warning extends to people with no diagnosed coronary artery disease, because coronary disease can be silent. (Source 9)
• When nebivolol is being taken alongside clonidine, the label directs that nebivolol be stopped several days before clonidine is tapered, to avoid a rebound rise in blood pressure. (Source 6)
• We found no literature describing dependence on nebivolol or a withdrawal syndrome in the sense used for sedatives or opioids. The documented risk of stopping is cardiac rebound, not drug craving or withdrawal symptoms, and the label frames it as a cardiac risk. (Source 9)

What goes wrong

As a class, starting hypertension treatment with a beta-blocker gives smaller cardiovascular benefit than other drug classes and more treatment withdrawals for side effects than renin-angiotensin blockers. (Source 10)

• Systematic review, Moderate certainty.
• Size: 13 randomised controlled trials; 10,828 participants in the comparison against renin-angiotensin system inhibitors.
• Who: Adults with hypertension.
• How long: At least one year per trial.
• Result: Discontinuation for adverse events RR 1.41 (95% CI 1.29 to 1.54) versus renin-angiotensin system inhibitors, moderate certainty; stroke higher than calcium-channel blockers (RR 1.24, 95% CI 1.11 to 1.40) and than renin-angiotensin inhibitors (RR 1.30, 95% CI 1.11 to 1.53). The review notes it found no outcome trials of nebivolol, so this is a class finding driven by atenolol, not a nebivolol finding.
• Funding: not stated.

Participants taking beta-blockers were more likely to discontinue treatment due to adverse events than participants taking RAS inhibitors (RR 1.41, 95% CI 1.29 to 1.54; moderate-certainty evidence)

In placebo-controlled hypertension trials, fatigue, headache, dizziness, nausea and bradycardia were more common on nebivolol than placebo, mostly at higher doses. (Source 11)

• Official position, Moderate certainty.
• Size: 1,597 nebivolol-treated and 205 placebo-treated hypertensive patients across three 12-week monotherapy trials.
• Who: Adults with hypertension given 5 mg, 10 mg or 20-40 mg nebivolol.
• How long: The label describes three 12-week trials but captions the adverse-reaction table as incidence over 6 weeks; it does not say which window the percentages cover.
• Result: Rates as placebo / 5 mg / 10 mg / 20-40 mg: fatigue 1/2/2/5%, headache 6/9/6/7%, dizziness 2/2/3/4%, nausea 0/1/3/2%, bradycardia 0/0/0/1%, diarrhoea 2/2/2/3%. Discontinuation for adverse reactions 2.8% on nebivolol vs 2.2% on placebo, most often headache (0.4%), nausea (0.2%) and bradycardia (0.2%). Note the placebo group was small (n=205) relative to the nebivolol groups.
• Funding: not stated (manufacturer label text)

Limit of this finding: The label contradicts itself about how long these rates were collected over. The text calls them "three 12-week, placebo-controlled monotherapy trials", while the table above the numbers is captioned "Incidence (over 6 weeks)". The label never reconciles the two, so treat the percentages as short-term rates of unclear exposure length rather than a settled 12-week figure. The numbers themselves are reproduced as printed.

discontinuation of therapy due to adverse reactions was reported in 2.8% of patients treated with nebivolol and 2.2% of patients given placebo. The most common adverse reactions that led to discontinuation of BYSTOLIC were headache (0.4%), nausea (0.2%) and bradycardia (0.2%).

A narrative review of nebivolol in heart failure reports that typical beta-blocker side effects occurred at placebo rates except for bradycardia. (Source 12)

• Expert review, not systematic, Very low certainty.
• Size: Not stated; an expert review drawing on SENIORS and earlier trials.
• Who: Patients with heart failure and hypertension.
• How long: Not stated.
• Result: Bradycardia is identified as the exception to placebo-level tolerability. The review also reports no negative effects on chronic obstructive pulmonary disease, erectile function, or glucose and lipid metabolism. This is an expert summary with no stated search method, so it carries little weight on its own.
• Funding: not stated.

Limit of this finding: This is a narrative review, not new research: it has no stated search method and it is summarising other people's trials. Its heart-failure results, including the composite endpoint it mentions, come from the separately published SENIORS trial and belong to that trial, not to this paper. Treat the tolerability statement here as an author's summary rather than as pooled evidence.

Typical β-blocker-related adverse events are same as that with placebo, except for bradycardia.

People who metabolise CYP2D6 poorly reach far higher nebivolol exposure than extensive metabolisers, and several common medicines raise exposure further. (Source 5)

• Blood level study, Low certainty.
• Size: 20 studies with plasma concentration-time data after oral and intravenous nebivolol.
• Who: Healthy volunteers and patients, including people with chronic kidney disease and obesity.
• How long: Single and multiple dose pharmacokinetic studies.
• Result: Area under the concentration-time curve 15 times greater in poor than extensive CYP2D6 metabolisers; 3-fold greater in chronic kidney disease. Higher peak concentration, exposure and half-life when co-administered with bupropion, duloxetine, fluvoxamine, paroxetine, lansoprazole or fluoxetine. These are blood-level studies, not studies of harm itself.
• Funding: not stated.

was 15 times greater in poor metabolizers (PMs) than in extensive metabolizers (EMs).

Stopping nebivolol abruptly has been followed by severe worsening of angina, heart attack and ventricular arrhythmias in people with coronary artery disease. (Source 9)

• Official position, Low certainty.
• Size: Not quantified in the label.
• Who: Patients with coronary artery disease, and by extension those without overt coronary disease.
• How long: Not stated.
• Result: No rate is given. The label states these events have been reported after abrupt discontinuation of beta-blockers, with or without preceding worsening of angina, and directs that therapy not be stopped abruptly.
• Funding: not stated (manufacturer label text)

Do not abruptly discontinue BYSTOLIC therapy in patients with coronary artery disease. Severe exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following the abrupt discontinuation of therapy with β-blockers.

What the evidence supports

In elderly patients with heart failure, nebivolol reduced a composite of all-cause death or cardiovascular hospital admission by about 4 percentage points, but did not significantly reduce death alone. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 2,128 participants (1,067 nebivolol, 1,061 placebo)
• Who: Patients aged 70 or over with a history of heart failure - a hospital admission for heart failure in the previous year or a known ejection fraction of 35% or less. Mean age 76, 37% female, mean ejection fraction 36%, 35% had an ejection fraction above 35%, 68% had prior coronary heart disease.
• How long: Mean follow-up 21 months.
• Result: Primary composite 332/1,067 (31.1%) vs 375/1,061 (35.3%); hazard ratio 0.86 (95% CI 0.74-0.99), P=0.039 - an absolute difference of about 4.2 percentage points. All-cause death 169 (15.8%) vs 192 (18.1%), hazard ratio 0.88 (95% CI 0.71-1.08), P=0.21, not significant. Mean maintenance dose 7.7 mg nebivolol.
• Funding: not stated.

The primary outcome occurred in 332 patients (31.1%) on nebivolol compared with 375 (35.3%) on placebo [hazard ratio (HR) 0.86, 95% CI 0.74-0.99; P=0.039].

Nebivolol controls blood pressure at least as well as the most used antihypertensive classes. (Source 2)

• Systematic review, Low certainty.
• Size: 12,465 patients across 34 randomised double-blind trials (from 981 screened)
• Who: Adults aged 18 to 85 with systemic arterial hypertension; 17% Black, about 55% men, nearly 10% with diabetes.
• How long: Varied; literature searched to 31 July 2015.
• Result: For systolic pressure, nebivolol was superior to other beta-blockers and diuretics and no different from angiotensin receptor blockers or calcium channel blockers; for diastolic pressure it was more efficient than other beta-blockers, angiotensin receptor blockers, diuretics and calcium channel blockers. Insufficient studies for comparison against ACE inhibitors.
• Funding: not stated.

In SBP management, nebivolol was superior to other β-blockers and diuretics and showed no difference in efficacy when compared with angiotensin receptor blockers or calcium channel blockers.

What the evidence does not support

In the same trial, nebivolol did not significantly reduce death from any cause. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 2,128 participants.
• Who: Patients aged 70 or over with heart failure.
• How long: Mean 21 months.
• Result: 169 (15.8%) vs 192 (18.1%) deaths; hazard ratio 0.88 (95% CI 0.71-1.08), P=0.21.
• Funding: not stated.

Death (all causes) occurred in 169 (15.8%) on nebivolol and 192 (18.1%) on placebo (HR 0.88, 95% CI 0.71-1.08; P=0.21).

The same systematic review states there is no evidence that nebivolol reduces cardiovascular events or death in hypertension. (Source 2)

• Systematic review, Low certainty.
• Size: 12,465 patients across 34 randomised double-blind trials.
• Who: Adults with systemic arterial hypertension.
• How long: Varied.
• Result: The review found no studies proving benefit for cardiovascular or general mortality, acute myocardial infarction or stroke, and concluded trials with clinical outcomes should be performed before preferring this drug over others with established outcome data.
• Funding: not stated.

there is a lack of studies proving the benefit of this drug for controlling hypertension and reducing clinical outcomes such as cardiovascular (or general) mortality, acute myocardial infarction, or stroke

Against other second-generation beta-blockers, nebivolol showed no difference in blood-pressure reduction, though it was better tolerated and left heart rate higher. (Source 13)

• Meta-analysis, Low certainty.
• Size: 1,514 patients across 8 randomised controlled trials.
• Who: Hypertensive patients.
• How long: Not stated in the abstract.
• Result: No difference in reduction of systolic or diastolic blood pressure. Heart rate was significantly lower on the other second-generation beta-blockers than on nebivolol. Adverse events were less frequent on nebivolol.
• Funding: not stated.

No significant difference was demonstrated between nebivolol and other second-generation β blockers in the reduction of blood pressure, SBP, and DBP.

The Cochrane review of beta-blockers for hypertension found no outcome trials of nebivolol or the other newer vasodilating beta-blockers; its findings rest overwhelmingly on atenolol. (Source 14)

• Systematic review, Moderate certainty.
• Size: 13 randomised controlled trials; 40,245 participants taking beta-blockers, three-quarters of them on atenolol.
• Who: Adults with hypertension and no compelling indication for a beta-blocker.
• How long: Trials of at least one year; conducted between the 1970s and 2000s, most at high risk of bias.
• Result: No difference in all-cause mortality versus placebo (RR 0.99, 95% CI 0.88 to 1.11), and higher mortality than calcium-channel blockers (RR 1.07, 95% CI 1.00 to 1.14), both moderate-certainty. Total cardiovascular disease lower than placebo (RR 0.88, 95% CI 0.79 to 0.97, low certainty), driven by stroke (RR 0.80, 95% CI 0.66 to 0.96).
• Funding: not stated.

We found no outcome trials involving the newer vasodilating beta-blockers (e.g. nebivolol).

Where the research disagrees

Whether nebivolol's blood-pressure results justify treating it as a proven cardiovascular drug

• Cochrane Hypertension review authors (2017), A Cochrane systematic review of 13 randomised trials with GRADE certainty ratings, in which three-quarters of beta-blocker participants took atenolol: "We found no outcome trials involving the newer vasodilating beta-blockers (e.g. nebivolol)." and "Current evidence suggests that initiating treatment of hypertension with beta-blockers leads to modest CVD reductions and little or no effects on mortality. These beta-blocker effects are inferior to those of other antihypertensive drugs." (Source 10)
• Authors of a 2021 systematic review and meta-analysis of nebivolol in hypertension, A systematic review and meta-analysis of 34 randomised double-blind trials in 12,465 patients, with blood pressure rather than events as the outcome: "Nebivolol demonstrated at least similar control of blood pressure levels in hypertensive individuals when compared with drugs of the most used classes." - while also writing that "there is a lack of studies proving the benefit of this drug for controlling hypertension and reducing clinical outcomes such as cardiovascular (or general) mortality, acute myocardial infarction, or stroke" (Source 2)
• US labelling for BYSTOLIC (Allergan), A regulatory position; the label grants the indication on blood-pressure lowering and borrows outcome benefit from the antihypertensive classes generally: "There are no controlled trials demonstrating risk reduction with BYSTOLIC." (Source 15)

How much

• Reference intake: There is no reference intake for a prescription medicine; dosing is set by the prescriber. As a position, the US label starts most patients on 5 mg once daily, with or without food, and allows increases at 2-week intervals (DailyMed label for BYSTOLIC, Allergan, SPL version effective August 2024, retrieved 1 October 2026). (Source 7)
• Upper limit: No upper limit is set by a nutrition body. The label's maximum is 40 mg once daily, and it adds that more frequent dosing is unlikely to help; reduced starting doses of 2.5 mg once daily apply in severe renal impairment and moderate hepatic impairment (DailyMed label for BYSTOLIC, Allergan). (Source 7)
• Studied: SENIORS titrated nebivolol from 1.25 mg once daily up to 10 mg once daily in elderly heart-failure patients; the mean maintenance dose achieved was 7.7 mg. (Source 4)
• Studied: The three placebo-controlled hypertension monotherapy trials in the label used 5 mg, 10 mg and 20-40 mg daily over 12 weeks. (Source 11)

A common belief, and what the research shows

The belief: Nebivolol is a modern, better beta-blocker, so it must protect the heart at least as well as the beta-blockers used after a heart attack.

What the research shows: No trial has shown that. The US label states flatly: "There are no controlled trials demonstrating risk reduction with BYSTOLIC." The Cochrane review of beta-blockers for hypertension reports: "We found no outcome trials involving the newer vasodilating beta-blockers (e.g. nebivolol)." The nebivolol-specific systematic review says the same thing in its own words - "there is a lack of studies proving the benefit of this drug for controlling hypertension and reducing clinical outcomes such as cardiovascular (or general) mortality, acute myocardial infarction, or stroke". The only outcome trial of nebivolol, SENIORS, was in elderly heart failure, met a composite endpoint by a narrow margin (hazard ratio 0.86, 95% CI 0.74-0.99) and did not significantly reduce death. Better tolerated and better at lowering a number is not the same as better at preventing heart attacks.

Questions and answers

What is it?

Nebivolol is a prescription beta-blocker, usually sold as Bystolic. It is described as a third-generation beta-blocker because it is highly selective for beta-1 receptors on the heart and also relaxes blood vessels, unlike older beta-blockers such as atenolol. In the United States it is licensed only for high blood pressure. (Source 12)

What does it do in the body?

It blocks beta-1 adrenergic receptors, so the heart beats more slowly and less forcefully, and it widens blood vessels. The manufacturer's label is unusually frank that exactly how it lowers blood pressure has not been definitively established, and lists five possible contributors including reduced sympathetic outflow from the brain and suppression of renin. A systematic review attributes some of the vessel relaxation to nitric oxide released from the vessel lining. (Source 1)

Is it good or bad for you?

It reliably lowers blood pressure and is comparatively well tolerated - across 34 trials it matched or beat other classes, and in a meta-analysis against other beta-blockers it caused fewer adverse events. The gap is in outcomes: the Cochrane review of beta-blockers for hypertension found no outcome trials of nebivolol at all, and the label says there are no controlled trials showing it reduces risk. For the beta-blocker class as a whole, starting hypertension treatment with one gave smaller cardiovascular benefit than other classes. The one outcome trial in nebivolol's favour, SENIORS, was in elderly heart failure. (Source 14)

How do you get more of it?

Only on prescription. As a position, the label starts most people on 5 mg once daily, with or without food, with increases allowed at two-week intervals up to 40 mg, and lower starting doses of 2.5 mg in severe kidney impairment or moderate liver impairment. No food or supplement contains it. This is not a recommendation about dose. (Source 7)

If it is harmful, what reduces it?

It clears from the body once stopped, but it should not be stopped suddenly. The label warns that abrupt discontinuation of beta-blockers in people with coronary artery disease has been followed by severe worsening of angina, heart attack and ventricular arrhythmias, sometimes with no warning, and extends that caution to people without known coronary disease. Coming off it is done by tapering under medical supervision. (Source 9)

Why might someone be low in it or missing it?

The amount in your blood on a given dose varies enormously between people. CYP2D6 poor metabolisers reach roughly 15 times the exposure of extensive metabolisers, and exposure is about three times higher in chronic kidney disease, so some people are effectively on a much larger dose than the label number suggests and others on a much smaller one. Other medicines that inhibit CYP2D6 push levels up. People may also be taken off it for bradycardia, severe hepatic impairment or because another class suits them better. (Source 5)

Which whole foods contain it or feed it?

Does not apply - no whole food contains nebivolol or anything that produces it. Food affects it only in that it does not need to be taken with food: the label states it can be taken with or without. We found no documented grapefruit or supplement interaction for nebivolol, though that reflects a lack of studies rather than proof of none. (Source 7)

What happens if you do not have it?

Nothing happens from lacking the drug itself - the body does not need it. What matters is the condition. In SENIORS, among elderly patients with heart failure given placebo instead, 35.3% died or were admitted to hospital for cardiovascular reasons over a mean 21 months, against 31.1% on nebivolol. In hypertension the untreated risk is of strokes and heart attacks, but the evidence that nebivolol in particular prevents those does not exist. (Source 3)

How can you test for it?

There is no blood test for nebivolol used in clinical care. Treatment is judged by its effects - blood pressure and heart rate - and the label instructs that the dose be individualised and monitored during up-titration. CYP2D6 genotyping would in principle predict who gets far higher exposure, and a pharmacokinetic review documents a 15-fold difference in exposure between poor and extensive metabolisers, but we found no evidence that genotyping before prescribing changes outcomes, and it is not required by the label. (Source 7)

We searched: We searched for therapeutic drug monitoring and CYP2D6 pharmacogenomic testing for nebivolol via PubMed queries on nebivolol pharmacokinetics, CYP2D6 poor metabolisers and drug interactions, and read the 2023 systematic review of nebivolol pharmacokinetics and the full US label; neither describes a validated clinical test.

References

1. Allergan, Inc., via DailyMed (US FDA structured product label). BYSTOLIC (nebivolol hydrochloride) tablet - Clinical Pharmacology, Mechanism of Action. 2024. Read the source
2. American Journal of Cardiovascular Drugs. Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis. 2021. PMID 32710438, DOI 10.1007/s40256-020-00422-0. Read the source
3. European Heart Journal. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). 2005. PMID 15642700, DOI 10.1093/eurheartj/ehi115. Read the source
4. European Heart Journal. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) - methods and population. 2005. PMID 15642700, DOI 10.1093/eurheartj/ehi115. Read the source
5. Drug Metabolism Reviews. Clinical pharmacokinetics of nebivolol: a systematic review. 2023. PMID 37849071, DOI 10.1080/03602532.2023.2271195. Read the source
6. Allergan, Inc., via DailyMed (US FDA structured product label). BYSTOLIC (nebivolol hydrochloride) tablet - Drug Interactions. 2024. Read the source
7. Allergan, Inc., via DailyMed (US FDA structured product label). BYSTOLIC (nebivolol hydrochloride) tablet - Dosage and Administration. 2024. Read the source
8. Allergan, Inc., via DailyMed (US FDA structured product label). BYSTOLIC (nebivolol hydrochloride) tablet - Warnings and Precautions (highlights). 2024. Read the source
9. Allergan, Inc., via DailyMed (US FDA structured product label). BYSTOLIC (nebivolol hydrochloride) tablet - Warnings and Precautions, Abrupt Cessation of Therapy. 2024. Read the source
10. Cochrane Database of Systematic Reviews. Beta-blockers for hypertension (Cochrane systematic review) - withdrawals due to adverse events and authors' conclusions. 2017. PMID 28107561, DOI 10.1002/14651858.CD002003.pub5. Read the source
11. Allergan, Inc., via DailyMed (US FDA structured product label). BYSTOLIC (nebivolol hydrochloride) tablet - Adverse Reactions, placebo-controlled hypertension trials. 2024. Read the source
12. Expert Opinion on Investigational Drugs. Nebivolol for the treatment of heart failure. 2011. PMID 21980961, DOI 10.1517/13543784.2011.625011. Read the source
13. Journal of International Medical Research. Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials. 2020. PMID 33081551, DOI 10.1177/0300060520931625. Read the source
14. Cochrane Database of Systematic Reviews. Beta-blockers for hypertension (Cochrane systematic review). 2017. PMID 28107561, DOI 10.1002/14651858.CD002003.pub5. Read the source
15. Allergan, Inc., via DailyMed (US FDA structured product label). BYSTOLIC (nebivolol hydrochloride) tablet - Indications and Usage. 2024. Read the source